Biogen and Denali Therapeutics limit the development of their experimental Parkinson’s disease drug BIIB122 after the therapy failed to meet primary and secondary endpoints in a Phase 2b clinical trial.
FDA says a Bolton Medical recall of its RelayPro thoracic stent graft system is Class 1.
Biogen and Denali Therapeutics limit the development of their experimental Parkinson’s disease drug BIIB122 after the therapy failed to meet primary and secondary endpoints in a Phase 2b clinical trial.
FDA says a Bolton Medical recall of its RelayPro thoracic stent graft system is Class 1.
FDA publishes for reference only an International Council for Harmonization template on a clinical electronic structured harmonized protocol.
Four stakeholders comment to FDA on ways to increase patient access to nonprescription drugs.
